109568
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
非小细胞肺癌患者中辐射诱导的 miR-208a 与癌症复发及死亡风险之间的关联
Authors Ji W, Bi Y, Zheng Q, Sun R, Dai K
Received 3 June 2025
Accepted for publication 19 September 2025
Published 11 October 2025 Volume 2025:18 Pages 6203—6209
DOI https://doi.org/10.2147/IJGM.S538351
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Dana Kristjansson
Wenjing Ji, Yanzhi Bi, Qian Zheng, Ruirui Sun, Kejun Dai
Oncology Department, Changzhou Cancer Hospital, Changzhou City, Jiangsu Province, 213000, People’s Republic of China
Correspondence: Kejun Dai, Oncology Department, Changzhou Cancer Hospital, No. 68 Honghe Road, Xinbei District, Changzhou City, Jiangsu Province, 213000, People’s Republic of China, Email yhdaxx520@163.com
Background: Existing experimental evidence suggested that the miR-208a expression in tumor tissue from non-small cell lung cancer (NSCLC) was significantly high after radiotherapy in vitro and in vivo, indicating a potential role for predicting NSCLC progression or recurrence. However, its prognostic value has not been fully confirmed among patients with NSCLC.
Aim: We explored the association of serum miR-208a level with adverse events including cancer recurrence and/or metastasis and cancer death during a follow-up for 36 months after radiotherapy.
Methods: We identified the serum level of miR-208a from 46 patients before and after surgical treatment combined with radiotherapy in NSCLC patients. The association between serum miR-208a and risk for the cancer recurrence and/or metastasis and cancer death among these patients were examined by Kaplan-Meier and multivariable Cox analysis.
Results: The comprehensive outcomes during the follow-up period for 3 years including cancer recurrence and/or cancer metastasis and cancer death were 13 (28.3%) and 8 (17.4%), respectively. Kaplan-Meier analysis suggested that a high serum miR-208a level after radiotherapy tended to have a higher rate of cancer recurrence and/or cancer metastasis and a higher risk of cancer death than those with a low level of serum miR-208a. Furthermore, our multivariable Cox analysis suggested that elevated serum miR-208a levels were associated with an increased risk for cancer recurrence and/or cancer metastasis (HR=7.5, 95% CI: 2.5– 24.9, P< 0.01) and cancer death risk (HR=5.3, 95% CI: 1.7– 18.5, P< 0.05) after age, gender, smoking, drinking and tumor node metastasis (TNM) stage were controlled for.
Conclusion: This study further provided evidence that elevated serum miR-208a levels after radiotherapy were associated with a high risk for cancer recurrence and/or metastasis and death among NSCLC patients.
Keywords: radiotherapy, non-small cell lung cancer, microRNAs, recurrence, death
Oncology Department, Changzhou Cancer Hospital, Changzhou City, Jiangsu Province, 213000, People’s Republic of China
Correspondence: Kejun Dai, Oncology Department, Changzhou Cancer Hospital, No. 68 Honghe Road, Xinbei District, Changzhou City, Jiangsu Province, 213000, People’s Republic of China, Email yhdaxx520@163.com
Background: Existing experimental evidence suggested that the miR-208a expression in tumor tissue from non-small cell lung cancer (NSCLC) was significantly high after radiotherapy in vitro and in vivo, indicating a potential role for predicting NSCLC progression or recurrence. However, its prognostic value has not been fully confirmed among patients with NSCLC.
Aim: We explored the association of serum miR-208a level with adverse events including cancer recurrence and/or metastasis and cancer death during a follow-up for 36 months after radiotherapy.
Methods: We identified the serum level of miR-208a from 46 patients before and after surgical treatment combined with radiotherapy in NSCLC patients. The association between serum miR-208a and risk for the cancer recurrence and/or metastasis and cancer death among these patients were examined by Kaplan-Meier and multivariable Cox analysis.
Results: The comprehensive outcomes during the follow-up period for 3 years including cancer recurrence and/or cancer metastasis and cancer death were 13 (28.3%) and 8 (17.4%), respectively. Kaplan-Meier analysis suggested that a high serum miR-208a level after radiotherapy tended to have a higher rate of cancer recurrence and/or cancer metastasis and a higher risk of cancer death than those with a low level of serum miR-208a. Furthermore, our multivariable Cox analysis suggested that elevated serum miR-208a levels were associated with an increased risk for cancer recurrence and/or cancer metastasis (HR=7.5, 95% CI: 2.5– 24.9, P< 0.01) and cancer death risk (HR=5.3, 95% CI: 1.7– 18.5, P< 0.05) after age, gender, smoking, drinking and tumor node metastasis (TNM) stage were controlled for.
Conclusion: This study further provided evidence that elevated serum miR-208a levels after radiotherapy were associated with a high risk for cancer recurrence and/or metastasis and death among NSCLC patients.
Keywords: radiotherapy, non-small cell lung cancer, microRNAs, recurrence, death